Analyst: Eli Lilly price drop is a sign of competitive US insulin market

Eli Lilly has lowered the price of its cheapest insulin products in the US, and according to an analyst, this is a clear expression of the intense competition on the market.


The US-based pharmaceutical company Eli Lilly's price reduction on its already cheapest insulin products signifies the tough competition on the US insulin market, in which the company is fighting for its market share with, for instance, Denmark's Novo Nordisk.

So says Senior Chief Analyst at Sydbank Søren Løntoft Hansen to Marketwire.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs